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Chemokines are important components of cancer-related inflammation. In this issue of Cancer Cell, Chen
et al. report that the chemokine CCL18, produced by tumor-associated macrophages, promotes malignant
behavior and correlates with metastasis in human breast cancer. Unexpectedly, PITPNM3/Nir1, a molecule
unrelated to chemokine receptors, was identified as its elusive receptor.Recruitment of cells of the monocyte-
macrophage lineage is an important
step in the cancer-related inflammation
orchestrated to a large extent by chemo-
kines. Levels of tumor-associate macro-
phages (TAMs) are frequently associated
with a bad prognosis, as illustrated by
recent findings in Hodgkin’s lymphoma
(Steidl et al., 2010). Chemokines have
long been associated with cancer (Manto-
vani et al., 2010), where they play a key
role in orchestrating the recruitment and
positioning of leukocytes. Experiments
with gene-modified mice have now
unequivocally demonstrated that chemo-
kine-orchestrated leukocyte recruitment
is a key determinant of carcinogenesis.
However, their action is not restricted to
their eponymous function (chemotaxis).
Chemokines such as CCL2 contribute to
polarizing TAMs in a tissue repair/remod-
eling (M2-like) mode (Biswas and Manto-
vani, 2010). Chemokines also affect
stromal components and tumor cells. In
particular, by interacting with endothelialFigure 1. TAMs in Human Breast Carcinoma Have an M2-like
Phenotype that Includes the Production of CCL18
CCL18 interacts with a PITPNM3/Nir1-containing complex in tumors to
promote their adhesion to extracellular matrix (ECM), invasion, andmetastasis.
Work in preclinical models supports that IL-4 produced by Th2 cells plays a key
role in skewing macrophage polarization. Moreover, chemokines (CCL2 and
CCL5) and M-CSF are involved in monocyte recruitment, and TAMs are
a source of EGF in the tumor microenvironment.cells and by attracting leuko-
cytes, chemokines promote
angiogenesis.
Engagement of chemokine
receptors promotes tumor-
cell proliferation and survival
and guides them to sec-
ondary sites to form metas-
tasis. In addition, the
chemokine receptor CXCR2
is a reinforcing determinant
of cellular senescence.
Thus, chemokines mediate
cell-autonomous and nonau-
tonomous responses in
carcinogenesis (Kulbe et al.,
2007; Mantovani et al.,
2010). Chemokines act
downstream of oncogene434 Cancer Cell 19, April 12, 2011 ª2011 Elsactivation in transformed cells, but
stromal elements can represent an impor-
tant source of these mediators (e.g., De-
Nardo et al., 2009). Furthermore, chemo-
kines produced by cancer-associated
fibroblasts (CAFs) recruit T regulatory
cells (Treg), inducing metastatic progres-
sion of breast carcinoma cells (Tan et al.,
2011).
In this issue of Cancer Cell, Chen et al.
(2011) report that TAMs in human breast
cancer are the major source of the che-
mokine CCL18 (Figure 1). CCL18 is
induced by IL-4, IL-13 and IL-10 and is
therefore part of the chemokine repertoire
of M2-like polarized macrophages (Bis-
was and Mantovani, 2010) that have
been shown to drive breast cancer
progression and metastasis in preclinical
models (DeNardo et al., 2009; Pollard,
2004). Interestingly, the frequencies of
CCL18+ TAMs correlated with those of
infiltrating CD4+ T, a finding that may
mirror the pivotal role of Th2 cells in M2
polarization in a preclinical setting (De-evier Inc.Nardo et al., 2009). High intratumor and
circulating levels of CCL18 were also
associated with a worse prognosis in
a large series of over 500 breast carci-
noma patients. CCL18 elicits migration
of lymphocytes and monocytes, but in
this study, the prime targets were tumor
cells and the authors found that CCL18
augmented invasion and metastasis of
breast carcinoma cells.
As a general rule, chemokines interact
with seven transmembrane-domain G
protein-coupled receptors (GPCRs). The
CCL18 receptor has long been elusive.
Unexpectedly, Chen et al. (2011) now
report that CCL18 interacts with and
signals through PITPNM3/Nir1, a mole-
cule that belongs to the phosphatidyl-
inosytol transfer protein (PITP) family
with no apparent structural or functional
similarity to conventional GPCRs. Mem-
bers of the PITP-family contain a phos-
phatidylinositol transfer protein domain
(PIT), an acidic region/Ca+2 binding
domain, six transmembrane domains,and a C-terminal domain
that interacts with PYK2.
PITPNM3 and its Drosophila
homologous rdgB have been
implicated in the visual trans-
duction pathway. RdgB func-
tions downstream protein
kinase C, rhodopsin and
phospholipase C in flies, and
mutation in the PYK2-binding
domain of PITPNM3 causes
autosomal dominant cone
dystrophy (CORD5) in
humans.
This finding is provocative,
but not completely without
precedent. Several nonca-
nonical interactions were
observed in the chemokine
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Previewssystem. For instance, the chemokine
receptors CXCR4 and CCR5 interact
with gp120, acting as HIV coreceptors
and the chemokine CXCL16 interacts
with oxidized LDL. Chemokine receptors
can also form heterodimers with other
chemokine receptors (Thelen et al.,
2010) or with other membrane receptors
modulating their function. For instance,
CXCR2 and CXCR4 interacting with
CD74 become functional receptors for
the noncanonical chemokine macro-
phage migration inhibitory factor (MIF),
and one could entertain the possibility
that PITPNM3 forms a dimer with
a conventional signaling GPCR.
Previous studies (Soria and Ben-Bar-
uch, 2008) have shown that levels of
the monocyte-attracting chemokines
CCL2 and CCL5 are associated with
macrophage infiltration and prognosis.
Therefore, a comprehensive ‘‘chemoki-
nome’’ system biology perspective may
well be required to explore the clinical
significance of chemokine levels in
cancer.The results reported here shed new
light on the role of chemokines in cancer
and raise important questions. There is
no mouse counterpart of CCL18 on which
to rely for rigorous genetic approaches to
investigate its role in carcinogenesis.
CCL18 was found in other human
tumors, ovarian in particular. The present
findings call for an appraisal of its prog-
nostic significance in these pathologies.
The actual structure of the CCL18-recog-
nizing receptor complex will also need to
be further investigated. Finally, and no
less important, chemokine anticancer
therapeutic strategies have entered clin-
ical evaluation. In spite of stumbling
blocks (e.g., lack of mouse counterpart,
drugability of the receptor), CCL18 may
be added to the list of potential thera-
peutic targets.REFERENCES
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ABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-
ABLT315I mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer
Cell, that ‘‘switch-control’’ inhibitors block BCR-ABLT315I activity by preventing ABL from switching from the
inactive to active conformation.The BCR-ABL fusion protein is the
primary driver oncogene in the majority
of chronic myeloid leukemias (CML) and
also in about 25% of adult acute lympho-
blastic leukemias (ALL) (Druker et al.,
2001). This protein is expressed from a
fusion gene resulting from a reciprocal
translocation between chromosome 9
and 22 (t(9;22)(q34;q11)), the so-called
Philadelphia chromosome (Ph+). ABL
is a tyrosine kinase and its fusion toBCR causes constitutive activation,
driving hematopoietic cell transformation
through activation of multiple signaling
pathways. The treatment of CML was
revolutionized by the development of ima-
tinib, a small molecular-weight drug that
inhibits ABL and mediates durable hema-
tologic and cytologic responses in CML
patients. The importance of imatinib
cannot be underestimated, because as
the first tyrosine kinase inhibitor (TKI) toachieve responses in cancer patients, it
provided a paradigm shift in cancer
treatment.
Although imatinib changed the clinical
management of CML, some patients
eventually fail on therapy due to acquired
resistance. Resistance can be mediated
by secondary mutations in BCR-ABL
that block imatinib binding through steric
hindrance or by switching ABL into the
active conformation. Like imatinib, thel 19, April 12, 2011 ª2011 Elsevier Inc. 435
